OncoImmune Overview

  • Founded
  • 2000
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $462M
Latest Deal Amount

OncoImmune General Information

Description

Operator of a clinical-stage biopharmaceutical company engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease. The company's offerings include recombinant fusion protein that targets a novel immune pathway checkpoint, enabling doctors to help with treating diseases targeting the immune system.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Primary Office
  • 9430 Key West Avenue
  • Suite 113
  • Rockville, MD 20850
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoImmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 01-Dec-2020 $462M 0000 00000 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series B) 09-Sep-2020 0000 0000 00000 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series A1) 22-May-2020 000 0000 0000 Completed Clinical Trials - Phase 3
3. Grant 30-Jul-2018 000.00 0000 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 12-Jan-2017 $15M $15M 0000 Completed Clinical Trials - Phase 2
1. Early Stage VC Completed Startup
To view OncoImmune’s complete valuation and funding history, request access »

OncoImmune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A1 000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A 2,601,833 $0.000100 $3.84 $3.84 1x $3.84 4.52%
To view OncoImmune’s complete cap table history, request access »

OncoImmune Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
3E Bioventures Capital Venture Capital Minority 000 0000 000000 0
GBA Capital PE/Buyout Minority 000 0000 000000 0
GF Xinde Investment Management Venture Capital Minority 000 0000 000000 0
HM Capital Other Minority 000 0000 000000 0
Kaitai Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »